Leading U.S. biotechnology stock: Amgen (AMGN) (1980)

Amgen Inc. (NASDAQ: AMGN) is George B. Dr. Rathmann (former Abbott executive) initiated the establishment in 1980 and is headquartered in Thousand Oaks, California, with 17,900 full-time employees (April 2015).

amgen logo

Amgen Amgen (AMGN) company’s main business:

American Amgen , like Novartis , Merck , Gilead, etc., is a leading global biotechnology and biopharmaceutical giant. The company’s mission is to use cytology and molecular biology technology to research and develop high-efficiency , Disease treatment drugs with low side effects. The company’s products are mainly sold to hospitals, pharmacies, hemodialysis centers and other medical institutions in Europe and the United States. As one of the world’s largest biopharmaceutical companies, “Amgen” is a leader in the global biopharmaceutical industry and has strong R&D capabilities and product advantages. It insists on developing in the field of disease treatment biotechnology. The fields involved are human genome, cancer, neuroscience and small molecule chemistry, etc.; but there are still great risks in the development of new products.

Amgen Amgen (AMGN):

  • In the 1980s, as the company’s main products were in the R&D and clinical trials stage, there was no product on the market, so it had to raise funds through public offerings in 1983, 1986, and 1987 to maintain the company’s survival.
  • In 1988, Gordon M. When Mr. Binder took over as CEO of Amgen, the company had only 479 employees and no products were launched.
  • In June 1989, Amgen’s first product of AMGN, recombinant human erythropoietin (erythropoietin, EPO) was approved by the US FDA for the treatment of anemia caused by chronic renal failure and HIV infection .
  • In February 1991, the company’s second product, recombinant granulocyte colony stimulating factor (filgrastim, G-CSF) was approved by the US FDA, and its indication was tumor chemotherapy-induced neutropenia. In 1992, Amgen entered the Fortune 500 for the first time, and the company’s product sales exceeded US$1 billion for the first time that year.
  • In the 2000 Fortune 500 ranking, Amgen ranked 455. In 2000, it ranked 21st among the top 50 global pharmaceutical companies.
  • In December 2001, the management of “Amgen” announced that it had acquired Immunex “Immunex”, another top biotechnology company in the United States with a product potential of “big bomb” drugs at a sky-high price of US$16 billion. The merger of two biotech companies with the most advanced technology and most competitive products in the world has greatly stimulated the US stock market.
  • In May 2003, Amgen purchased approximately 20% of Tularik’s shares in order to cooperate in the development of new drugs for the treatment of cancer.
  • On March 29, 2004, Amgen announced that it would acquire Tularik, a South San Francisco-based company that develops drugs for the treatment of esophageal cancer, inflammation, diabetes, and obesity, with shares valued at US$1.3 billion. 80% of the shares (holding up to 100%, wholly-owned subsidiary). Amgen is seeking to develop drugs for the treatment of cancer, autoimmune and metabolic diseases, and Duraric has advantages in these three aspects, because all new drugs developed by Duraric use gene technology to achieve therapeutic goals.
  • On October 7, 2015, Johnson & Johnson (JNJ) was rumored to acquire Amgen (AMGN), details to be disclosed.

The two most successfully commercialized biotech drugs EPO (trade name EPOGEN) and G-CSF (trade name NEUPOGEN) of Amgen’s AMGN have not only benefited countless hemodialysis patients and cancer chemotherapy patients, but also brought the company With huge profits, the company has grown rapidly.

Amgen Amgen (AMGN) investment:

Company official website-

Home of American Stocks- https : //

Baidu Encyclopedia-

Snowball US Stocks- http : //

Yahoo Finance- http : //

Notify of
Inline Feedbacks
View all Intels

British container ship shipping company: Global Ship Lease (GSL)

Chinese stocks: cosmetics e-commerce-Jumei International (JMEI)-delisting (2010)